Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Recently, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication that warns of an increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild to moderate glucose elevations (euglycemic DKA [euDKA]) associated with the use of all the approved sodium-glucose cotransporter 2 (SGLT2) inhibitors (1).This Communication was based on 20 clinical cases requiring hospitalization captured between March 2013 and June 2014 in the FDA Adverse Event Reporting System database.The scarce clinical data provided suggested that most of the DKA cases were reported in patients with type 2 diabetes (T2D), for whom this class of agents is indicated; most likely, however, they were insulintreated patients, some with type 1 diabetes (T1D).The FDA also identified potential triggering factors such as intercurrent illness, reduced food and fluid intake, reduced insulin doses, and history of alcohol intake.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with either T1DM or T2DM taking insulin are at particular risk, with the greatest risk for ketoacidosis in T1DM.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
In the citing paper
“Euglycemic ketoacidosis with minimal to no elevation in blood glucose levels may occur in patients taking SGLT2 inhibitors due to increased fatty acid oxidation and glucagon release along with decreased insulin secretion (89,90).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
Citations
Cites
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 4×
“Thus, in SGLT2-treated T2D patients (17), the lower insulin-to-glucagon ratio stimulated lipolysis (circulating FFAs were ;40% higher during the meal) and enhanced lipid oxidation (by 20% on av-”
BackgroundInfluentialSelf-citationPeters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · cited 1×
“of the euglycemic insulin clamp, as a result of attenuated glucotoxicity (21).”
BackgroundInternational Textbook of Diabetes Mellitus
(2004) · Wiley eBooks · doi:10.1002/0470862092 · Cited by 725
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
Erondu, N., Desai, M., Ways, K., & Meininger, G. (2015) · Diabetes Care · doi:10.2337/dc15-1251 · Cited by 324
Euglycaemic Diabetic Ketoacidosis
Munro, J. F., Campbell, I. W., McCuish, A. C., & Duncan, L. J. P. (1973) · BMJ · doi:10.1136/bmj.2.5866.578 · Cited by 323
Insulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“In contrast, plasma glucagon concentrations increased significantly, partly because of a diminished paracrine inhibition by insulin (18) and possibly also because of decreased SGLT2-mediated glucose transport intoa-cells (19).”
Background
Cited by
Items 301–400 of 685
Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases
Gulsin, G. S., Graham-Brown, M. P. M., Squire, I. B., Davies, M. J., & McCann, G. P. (2021) · Heart · doi:10.1136/heartjnl-2021-319185 · Cited by 12
Beyond type 2 diabetes: sodium glucose co‐transporter‐inhibition in type 1 diabetes
Biester, T., Kordonouri, O., & Danne, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13659 · Cited by 13
“Again, the mechanism of euDKA is presently not yet completely understood.(36) In former therapy guidelines, patients were advised to check ketone in urine to evaluate their catabolic status.”
BackgroundLaursen, H. V. B., Røikjer, J., Dal, J., & Jensen, M. H. (2020) · Current Drug Safety · doi:10.2174/1574886315666200819114629 · Cited by 13
The safety of empagliflozin plus metformin for the treatment of type 2 diabetes
Scheen, A. J. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1497159 · Cited by 13
Sodium–glucose cotransporter 2 inhibitors and diabetic ketoacidosis
Bloomgarden, Z. T. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12353 · Cited by 11
Mendelsohn, R. A., Taveras, A. N., Mazer, B., & Clayton, L. M. (2020) · Clinical Practice and Cases in Emergency Medicine · doi:10.5811/cpcem.2020.4.46056 · Cited by 12
SGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies
Ma, Y., Zhao, Q., Peng, H., Nalisa, D. L., Shan, P., & Jiang, H. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2805098 · Cited by 11
“While SGLT2i increases the risk of ke-togenesis and DKA, which deserves special attention as a serious adverse event in patients with T1DM [ 11–13].”
BackgroundMethodResultInfluentialYadav, J., Ahsan, F., Panda, P., Mahmood, T., Ansari, V. A., & Shamim, A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998271026231127051545 · Cited by 13
Borrego, M. R., Lu, Y., Reyes-Cosmelli, F., Park, Y. H., Yamashita, T., Chiu, J. W. Y., Airoldi, M., Turner, N. C., Fein, L. E., Ghaznawi, F., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07405-8 · Cited by 11
“These rat models showed no indications of a. drug-drug interactions and no signs of euglycemic diabetic ketoacidosis; however, there is a risk of euglycemic diabetic ketoacidosis with SGLT2i treatment and regular monitoring is still required [19].”
BackgroundDashora, U. K., Gallagher, A., Dhatariya, K., Winocour, P. H., & Gregory, R. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.112 · Cited by 12
“ABCD strongly advise that patients with type 1 diabetes prescribed an SGLT-2 inhibitor should give informed consent that makes them fully aware of the potential for euglycaemic diabetic ketoacidosis (euDKA), the precipitating factors, the warning symptoms and signs and the preventive measures to adopt.(23,39) Written…”
BackgroundInfluentialLahiri, S. W. (2017) · Clinical Diabetes · doi:10.2337/cd17-0083 · Cited by 11
“Recently, additional adverse events, including euglycemic diabetic ketoacidosis with drugs from this class (34), an increase in bone fractures with canagliflozin (35), and toe/ metatarsal amputations with canagliflozin (36), have been reported.”
BackgroundA Case of Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus and COVID-19
Morrison, N. J., Barnett, K., Tantum, J., Morrison, H., & Whalen, M. (2020) · Cureus · doi:10.7759/cureus.12029 · Cited by 11
“IL-6 is a proposed dynamic cause of ketone production through the induction of cellular insulin resistance in hepatocytes [4,12-14].”
BackgroundFerrannini, E., & Rosenstock, J. (2021) · Diabetes Care · doi:10.2337/dc20-0913 · Cited by 11
“DKA is rarely fatal but is a serious adverse event of major clinical impact (6).”
BackgroundSelf-citationAlmazrouei, R. A., AlKindi, F., Al-Shamsi, A. M., Dawoud, T. H., Chaaban, A., & Rahman, M. U. (2021) · Oman Medical Journal · doi:10.5001/omj.2022.17 · Cited by 11
“Medicine (Baltimore) 2019 Jan;98(3):e14150.”
Garnica-Cuéllar, J. C., Lavalle-González, F. J., Magaña-Serrano, J. A., Almeda-Valdés, P., Canto, J. A. C., Chávez-Iñiguez, J. S., Garza-García, C. A., González-Chávez, A., González-Gálvez, G., Medina-Chávez, J. H., et al. (2022) · Gaceta Médica de México · doi:10.24875/gmm.m21000596 · Cited by 15
Acute Metabolic Complications of Diabetes
Newland‐Jones, P., Patel, M. A., & Dhatariya, K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch41 · Cited by 11
Паневин, Т. С., Елисеев, М. С., Shestakova, M. V., & Nasonov, E. L. (2020) · Terapevticheskii arkhiv · doi:10.26442/00403660.2020.05.000633 · Cited by 12
“Таким образом, эугликемический диабетический кетоацидоз при использовании иНГЛТ-2 может рассматриваться как прогнозируемая и предотвратимая проблема [97].”
Lee, D., Seo, G., Kim, Y., Min, J. Y., & Yee, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16635 · Cited by 10
“8 However, evidence comparing the clinical features and severity of DKA between SGLT2i users and non-users remains limited.”
Developing a Protocol for Management of Euglycemic Diabetic Ketoacidosis
Cardona, Z., Friedman, J. G., Kamal, N., Oakes, D. J., Wallia, A., Aleppo, G., Brown, S., Makowski, C. T., Ritter, K., & Szmuilowicz, E. D. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01604-3 · Cited by 15
“This leads to insufficient endogenous production of insulin, which in the setting of elevated levels of counter-regulatory hormones such as cortisol, epinephrine and glucagon, leads to fatty acid metabolism and ketone production despite near-normal blood glucose levels [ 3, 12].”
Diabetic ketoacidosis precipitated by COVID-19 in patient with newly diagnosed diabetes mellitus
Xhardo, E., Kapisyzi, P., & Rada, A. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.5.2021.241521 · Cited by 10
“Also alcohol abuse and drugs like SGLT-2 inhibitors [9] can precipitate an DKA episode.”
BackgroundScheen, A. J. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1315102 · Cited by 10
“This side effect may contribute to increase the risk of euglycemic ketoacidosis with SGLT2i, especially in presence of lack of insulin [76,77].”
BackgroundRizos, C. V., Filippatos, T. D., & Elisaf, M. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1418325 · Cited by 10
Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2
Scheen, A. J. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30005-1 · Cited by 15
Melmer, A., Kempf, P., Lunger, L., Pieber, T. R., Mader, J. K., Stettler, C., Tilg, H., Ebenbichler, C. F., & Laimer, M. W. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13439 · Cited by 10
“However, a higher risk of euglycaemic ketosis and keto-acidosis was reported.(1) The present study investigated the short-term effects of dapagli-”
BackgroundThe Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies
Dhindsa, D. S., Sandesara, P. B., & Shapiro, M. D. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00160 · Cited by 10
“Briefly, this complication is, in part, a result of persistent glycosuria triggering a sequence of metabolic changes that leads to decreased insulin production and increased glucagon secretion, stimulating enhanced ketogenesis (26).”
BackgroundWong, Y. C., Liu, K., & Lee, C.-L. (2021) · Medicine · doi:10.1097/md.0000000000025590 · Cited by 10
“3 and hepatic ketogenesis rate.([2]) An ensuing increase in the level of ketone bodies increases blood acidity, thereby causing alkaline and electrolyte derangements.”
BackgroundYates, T., Henson, J., Sargeant, J., King, J. A., Ahmad, E., Zaccardi, F., & Davies, M. J. (2021) · Translational Medicine and Exercise Prescription · doi:10.53941/tmep.v1i1.33 · Cited by 10
van Ruiten, C. C., Hesp, A. C., & van Raalte, D. H. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.03.031 · Cited by 11
Arrieta, F., Iglesias, P., Pedro‐Botet, J., Becerra, A., Ortega, E., Obaya, J. C., Nubiola, A., Maldonado, G. F., Campos, M. D. M., Petrecca, R., et al. (2018) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2018.05.002 · Cited by 16
SGLT2-inhibitors and euglycemic diabetic ketoacidosis in COVID-19 pandemic era: a case report
Secinaro, E., Ciavarella, S., Rizzo, G. S., Porreca, E., & Vitacolonna, E. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01909-9 · Cited by 10
Shivaswamy, V., Kedia, R., Kulkarni, S., & Ross, M. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s85748 · Cited by 10
“1,300 patients, there were eight events consistent with ketoacidosis, of which three events were with EMPA and the remaining five events with placebo group.(34) The EMPRA-REG OUTCOME Trial of .”
Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes
Isaacs, D. M., Yager, S., Parker, M., Wolfe, L., Luxenburg, J., & Lekic, S. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018816728 · Cited by 10
Kuchay, M. S., Mishra, S. K., & Mehta, Y. B. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.04.016 · Cited by 11
Insulin’s Role in Diabetes Management: After 90 Years, Still Considered the Essential “Black Dress”
Cefalu, W. T., Rosenstock, J., LeRoith, D., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dci15-0023 · Cited by 10
“A commentary by Rosenstock and Ferrannini (13) published in the September issue of Diabetes Care”
BackgroundSelf-citationKetosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy
Gao, F. M., Kishore, K., Pandey, D. B., Jahanabadi, H., Stevens, M., Lecamwasam, A., Bellomo, R., Churilov, L. P., & Ekinci, E. I. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70029 · Cited by 9
“31 Finally, our study implies ketosis rates are low in heart failure patients, who are the main patient group where these medications are currently recommended for inpatient use.”
Zaghloul, N., Awaisu, A., Mahfouz, A., Alyafei, S., & Elewa, H. F. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01464-x · Cited by 9
“They may also increase the risk of amputations [21, 22], metabolic acidosis [23, 24], and bone fractures [25].”
BackgroundGlucokinase activators and imeglimin: new weaponry in the armamentarium against type 2 diabetes
Sjöholm, Å. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004291 · Cited by 10
Miyauchi, M., Toyoda, M., & Fukagawa, M. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7945 · Cited by 9
“(17), the mechanisms underlying SGLT2 inhibitor-induced euDKA include the fact that insulin deficiency and resistance are both milder in comparison to DKA, causing less glucose overproduction and underutilization - resulting in blood glucose levels that are comparatively low.”
BackgroundFerrannini, E., Baldi, S., Frías, J. P., Guja, C., Hardy, E., Repetto, E., Jabbour, S. A., & DeFronzo, R. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13870 · Cited by 9
Self-citationSGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes
Chen, H., Birnbaum, Y., Ye, R., Yang, H., Bajaj, M., & Ye, Y. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07243-6 · Cited by 9
Euglycemic Diabetic Ketoacidosis (EDKA) in a Patient Receiving Dapagliflozin
Sethi, S. M. (2021) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2021.266 · Cited by 9
“Food and Drug Administration (FDA) had issued a report that clinicians should use SGLT-2 inhibitors cautiously because of its potential adverse outcome of euglycemic ketoacidosis (5).”
BackgroundNew insights into cellular links between sodium–glucose cotransporter‐2 inhibitors and ketogenesis
Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30327 · Cited by 9
Brust-Sisti, L. A., Rudawsky, N., Gonzalez, J., & Brunetti, L. (2022) · Pharmacy · doi:10.3390/pharmacy10060166 · Cited by 10
“Whereas both conditions stimulate ketosis through a lower insulin-to-glucagon ratio, SGLT2-induced euDKA is characterized by a nearly doubled renal glucose clearance rate [36].”
BackgroundKabadi, U. M. (2015) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2015.54026 · Cited by 9
“However, manufacturers of these drugs refute the significance of these reports by FDA and EMA based on the retrospective analysis of pre marketing clinical trials [110] [111].”
BackgroundRole of NMDA Receptors in Pancreatic Islets
Scholz, O., Welters, A., & Lammert, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-49795-2_7 · Cited by 10
Dhindsa, D. S., Mehta, A., Sandesara, P. B., Thobani, A., Brandt, S., & Sperling, L. S. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1197-6 · Cited by 9
Koyama, K., Anno, T., Kimura, Y., Kawasaki, F., Kaku, K., Tomoda, K., & Kaneto, H. (2024) · Journal of Diabetes Research · doi:10.1155/2024/8889415 · Cited by 8
“In DKA triggered by the usage of SGLT2 inhibitors, blood glucose levels may not be signi fi cantly elevated due to increase of urinary glucose excretion ( “ euglyce-mic DKA ” ) [26].”
BackgroundTsur, A., Leibowitz, G., Cohen, M. J., Cahn, A., & Pollack, R. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16545 · Cited by 9
Gliflozine – in Zukunft Kardioprotektiva?
Rauch‐Kröhnert, U., & Landmesser, U. (2021) · Der Internist · doi:10.1007/s00108-021-01083-0 · Cited by 8
Hitsuwari, T., Tsurutani, Y., Yamane, T., Sunouchi, T., Horikoshi, H., Hirose, R., Hoshino, Y., Watanabe, S., Katsuragawa, S., & Saitou, J. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8830-21 · Cited by 8
“In addition, ketone body reabsorption in the kidneys increases (30).”
BackgroundCombination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
Ahmann, A. (2015) · Drugs in Context · doi:10.7573/dic.212288 · Cited by 8
“The US Food and Drug Administration (FDA) has issued a warning that the risk of DKA may be increased with the use of SGLT2 inhibitors [31].”
InfluentialPatel, C. A., Bailey, R. A., Vijapurkar, U., Meininger, G. E., & Blonde, L. (2016) · BMC Health Services Research · doi:10.1186/s12913-016-1607-z · Cited by 9
“1 %) in randomized controlled trials involving SGLT2 inhibitors dapagliflozin (preliminary) and empagliflozin [35, 36].”
BackgroundSood, M., Simon, B. F., Ryan, K. F., & Zebrower, M. (2018) · AACE Clinical Case Reports · doi:10.4158/ep171860.cr · Cited by 9
Safety of sodium–glucose c otransporter 2 inhibitors in Asian type 2 diabetes populations
Davidson, J. A., Sukor, N., Hew, F., Mohamed, M., & Hussein, Z. B. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13915 · Cited by 9
England, C. Y., & Andrews, R. C. (2020) · Diabetic Medicine · doi:10.1111/dme.14217 · Cited by 8
Euglycemic Ketoacidosis in a Non-diabetic Patient After Tirzepatide Use: A Cautionary Tale
Singh, R. (2025) · Cureus · doi:10.7759/cureus.83187 · Cited by 7
“EKA typically arises when insulin levels are relatively low, but not enough to cause hyperglycemia, resulting in unchecked lipolysis and ketogenesis [7].”
Kilpatrick, E. S., Butler, A. E., Saeed, S., Alamuddin, N., Atkin, S. L., & Sacks, D. B. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01176-w · Cited by 7
“…with an increasing prevalence of euglycemic ketoacidosis due to factors including the use of sodium glucose transporter 2 (SGLT2) inhibitors [5], and a paucity of evidence confirming the 3mmol/L diagnostic threshold for blood ketones (BOHB) [2], a study verifying ketone thresholds and…”
BackgroundPirola, L., Górecka, K. M., Leandro, C. G., & Balcerczyk, A. (2024) · Endocrines · doi:10.3390/endocrines5040042 · Cited by 8
Schwartz, S. S., & Katz, A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s65588 · Cited by 8
“1%).(74) DKA is usually associated with marked hyperglycemia (.”
The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia
Kim, M.-K., Lee, E. J., Shin, H., Jung, H. S., Kim, T. K., Kim, T. N., Kwon, M. J., Lee, S. H., Rhee, B. D., & Park, J. H. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0659-1 · Cited by 7
Dapagliflozin for the treatment of type 1 diabetes mellitus
Pafili, K., Maltezos, E. S., & Παπάνας, Ν. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1339788 · Cited by 7
“cose) are generally considered vital for early diagnosis [94,100,101].”
BackgroundDapagliflozin and saxagliptin tablets for adults with type 2 diabetes
Scheen, A. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1389645 · Cited by 7
“As with other SGLT2is, the use of dapagliflozin may be associated with an increased risk of euglycemic diabetic ketoacidosis in patients with T2D with low residual insulin secretion, especially in certain circumstances such as during the postsurgical period [54].”
BackgroundSGLT inhibition in T1DM — definite benefit with manageable risk
Ferrannini, E., & Solini, A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.139 · Cited by 7
Self-citationSGLT2 Inhibitors: Rationale and Perspectives of Use in Heart Failure
Kobalava, Z. D., Lazarev, P. V., & Вадимовна, В. С. (2018) · Kardiologiia · doi:10.18087/cardio.2018.2.10087 · Cited by 7
Fieger, E., Fadel, K., Modarres, A. H., Wickham, E. P., & Wolver, S. E. (2020) · AACE Clinical Case Reports · doi:10.4158/accr-2020-0314 · Cited by 8
“EuDKA is a known risk of SGLT2 inhibitor therapy, initially described in a series of 20 cases between 2013 and 2014 published by the United States Food and Drug Administration (9).”
BackgroundJiang, Y., Li, Z., Yue, R., Liu, G., Yang, M., Long, C., & Yan, D. (2023) · Food & Function · doi:10.1039/d3fo02407e · Cited by 7
A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes
Gallwitz, B. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1382471 · Cited by 7
Evolution of Glucose-Lowering Drugs for Type 2 Diabetes
Krentz, A. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812019-4.00033-7 · Cited by 8
Allison, R. D., Goldstein, D., & Musso, M. W. (2019) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2019.03.011 · Cited by 7
Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult
Nolan, B. J., Varadarajan, S., Fourlanos, S., & Neoh, S. L. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.12.006 · Cited by 9
Chen, C.-F., Chen, Y., Chen, T., Chen, F.-Y., Yang, Y.-P., Wang, M., Huo, T., Chang, Y.-L., Tan, A. C., & Lin, C. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000354 · Cited by 8
Using adjuvant pharmacotherapy in the treatment of type 1 diabetes
Sjöholm, Å. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1939679 · Cited by 7
McCann, M., O'Brien, A., Larbalestier, R. I., & Davis, T. M. E. (2022) · Internal Medicine Journal · doi:10.1111/imj.15772 · Cited by 7
Leung, M., Rodrigues, P., & Roitman, D. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s370244 · Cited by 7
“The mechanism for SGLT2-induced DKA has been explained elsewhere.(25) At the time of diagnosis of our patient’s first DKA episode, it was not feasible to distinguish the causative agent (empagliflozin versus alpelisib).”
BackgroundRasalam, R. R., Abdo, S., Deed, G., O’Brien, R. C., & Overland, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14953 · Cited by 7
“nausea, vomiting, abdominal pain, malaise, shortness of breath) that have been reported, albeit infrequently, in patients with T2D taking SGLT2is.(117-119,121)”
BackgroundAlhassan, S., Rudoni, M. A., Alfonso-Jaume, M., & Jaume, J. C. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12885 · Cited by 7
“If the glycosuric effect is present beyond discontinuation of these drugs, euglycemic DKA may not be even suspected, less so predicted or prevented.(5) That is, if a diabetic patient not currently taking an SGLT2i becomes symptomatic for DKA while euglycemic, it would be very difficult for doctors unaware of the pheno…”
BackgroundSchwarzenbach, M., Bernhard, F. E., Czerlau, C., & Sidler, D. (2021) · World Journal of Transplantation · doi:10.5500/wjt.v11.i7.254 · Cited by 7
Etiologies and Outcomes of Diabetic Ketoacidosis in Cancer Patients: A Retrospective Analysis
Gandhi, A., Jeun, R., Wang, Z., Khan, S., Best, C. J., Lavis, V. R., & Thosani, S. (2025) · Cancers · doi:10.3390/cancers17172728 · Cited by 6
“SGLT2 inhibitors promote glycosuria and a shift toward ketone metabolism, and they have been associated with euglycemic DKA in patients with type 1 and type 2 diabetes [23–25].”
Abdulgayoom, M., Alshurafa, A., Kaddoura, R., Al-Mashdali, A. F., Mohamed, S. F., & Yassin, M. A. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70197 · Cited by 8
Sharma, A., Rengarajan, L. N., Narendran, P., Dhatariya, K., Kempegowda, P., & DEKODE Working Group (2025) · Diabetic Medicine · doi:10.1111/dme.70010 · Cited by 6
Liew, A., Bavanandan, S., Hao, C., Lim, S. K., Prasad, N., Sahay, M., Susantitaphong, P., Roberts, V., Wijewickrama, E. S., Wong, M. G., et al. (2025) · Nephrology · doi:10.1111/nep.70030 · Cited by 7
Euglycaemic ketoacidosis from an SGLT 2 inhibitor exacerbated by a ketogenic diet
Sinha, S., Gavaghan, D., & Yew, S. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50434 · Cited by 6
SGLT-2 inhibitors as adjunctive to insulin therapy in type 1 diabetes
Maj-Podsiadło, A., Cichocka, E., & Gumprecht, J. (2020) · Clinical Diabetology · doi:10.5603/dk.2020.0013 · Cited by 6
“A lower insulin to glucagone ratio stimulates ketogenesis and lipolysis (with circulating free fatty acid levels increased by 40% during a meal), which leads to increased lipid oxidation (on average by 20%) at the expense of carbohydrate oxidation [7].”
BackgroundUpdates on the Management of Hyperglycemia in Hospitalized Adult Patients
Razavi, L., & Omoregie, C. (2023) · Endocrines · doi:10.3390/endocrines4030037 · Cited by 7
“Treatment is similar to DKA with the addition of glucose-containing fluid replacement [76].”
BackgroundMethodEuglycemic diabetic ketoacidosis: The paradox of delayed correction of acidosis
Albert, S. G., Shrestha, E., & Wood, E. M. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102848 · Cited by 6
Rebordosa, C., Thomsen, R. W., Tave, A. K., Madsen, M., Beachler, D. C., Martinez, D. R., García‐Esteban, R., Plana, E., Tormos, A., FARSANI, S. F. F., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15429 · Cited by 6
Kishimoto, M., Yamaoki, K., & Adachi, M. (2019) · Case Reports in Endocrinology · doi:10.1155/2019/9415347 · Cited by 6
Sanusi, I., Sarnowski, A., Russell-Jones, D. L., & Forni, L. G. (2019) · Journal of Critical Care · doi:10.1016/j.jcrc.2019.12.007 · Cited by 7
Evidence-based therapeutics for hyperglycemia in hospitalized noncritically ill patients
Gracia‐Ramos, A. E., Carretero‐Gómez, J., Mendez, C. E., & Carrasco-Sánchez, F. J. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1997288 · Cited by 7
Miyazaki, M., Nakano, M., Takahashi, H., Isaka, Y., & Hiura, Y. (2024) · American Journal of Case Reports · doi:10.12659/ajcr.943945 · Cited by 7
“Free fatty acids are metabolized in the liver to produce ketone bodies [16].”
BackgroundYassin, S. A., & Aroda, V. R. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s121899 · Cited by 7
Lioudaki, E., Whyte, M., Androulakis, E. S., Stylianou, K., Daphnis, E., & Ganotakis, E. S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.731 · Cited by 6
Zwart, K., Velthuis, S., Polyukhovych, Y. V., Mosterd, A., Smidt, L. C. A., Serné, E. H., van Raalte, D. H., Elders, P. J. M., Handoko, M. L., & Oldenburg-Ligtenberg, P. C. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01580-9 · Cited by 7
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
Kataria, A., & Argyropoulos, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_25 · Cited by 7
Clinical Syndromes of Metabolic Acidosis
Krapf, R., Seldin, D. W., Hulter, H. N., & Alpern, R. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-815389-5.00015-0 · Cited by 8
New Diabetes Medications Raise New Perioperative Concerns for the Anesthesiologist
DeCou, J. A., & Sams, S. H. (2018) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002740 · Cited by 6
Woronow, D. I., Chamberlain, C. E., Houstoun, M., & Muñoz, M. A. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.04.012 · Cited by 5
Takahashi, H., Hatayama, S., & Izumi, T. (2025) · Internal Medicine · doi:10.2169/internalmedicine.6353-25 · Cited by 5
Martínez, J. J. G. (2016) · Medicina Clínica · doi:10.1016/s0025-7753(17)30619-x · Cited by 8
Tauseef, A., Asghar, M. S., Zafar, M., Lateef, N., & Thirumalareddy, J. (2020) · Cureus · doi:10.7759/cureus.10078 · Cited by 6
Metadata
- Authors
- Rosenstock, J., & Ferrannini, E.
- Affiliations
- Medical City Dallas Hospital (US)
- Istituto di Fisiologia Clinica (IT)
- Corresponding author
- Rosenstock, Julio
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-08-10
- Volume
- 38
- Issue
- 9
- Pages
- 1638-1642
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1955935325
- Cited by
- 664
- References
- 21
- Citations by year
- 2026: 23 · 2025: 33 · 2024: 55 · 2023: 36 · 2022: 43 · 2021: 68 · 2020: 89 · 2019: 79 · 2018: 67 · 2017: 75 · 2016: 77 · 2015: 18
- FWCI
- 68.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- euglycemic diabetic ketoacidosis, SGLT2 inhibitors, drug safety, type 2 diabetes, type 1 diabetes, insulin-treated patients, adverse drug reactions, risk factors, alcohol consumption, intercurrent illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.